{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:15:48Z","timestamp":1786979748917,"version":"build-2736575974"},"reference-count":90,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2024,1,13]],"date-time":"2024-01-13T00:00:00Z","timestamp":1705104000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,1,13]],"date-time":"2024-01-13T00:00:00Z","timestamp":1705104000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Strategic Academic Leadership Program"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Microbiol"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1007\/s00203-023-03752-0","type":"journal-article","created":{"date-parts":[[2024,1,12]],"date-time":"2024-01-12T22:02:24Z","timestamp":1705096944000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Immunology of gut microbiome and liver in non-alcoholic fatty liver disease (NAFLD): mechanisms, bacteria, and novel therapeutic targets"],"prefix":"10.1007","volume":"206","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4644-0816","authenticated-orcid":false,"given":"Stanislav Konstantinovich","family":"Gruzdev","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irina Viktorovna","family":"Podoprigora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oksana Anatolievna","family":"Gizinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,1,13]]},"reference":[{"issue":"1","key":"3752_CR1","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1002\/cld.1010","volume":"17","author":"SAM Albhaisi","year":"2021","unstructured":"Albhaisi SAM, Bajaj JS (2021) The influence of the microbiome on NAFLD and NASH (in Eng). Clin Liver Dis (hoboken) 17(1):15\u201318. https:\/\/doi.org\/10.1002\/cld.1010","journal-title":"Clin Liver Dis (hoboken)"},{"issue":"1","key":"3752_CR2","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1002\/cld.1045","volume":"17","author":"Y Ando","year":"2021","unstructured":"Ando Y, Jou JH (2021) Nonalcoholic fatty liver disease and recent guideline updates (in Eng). Clin Liver Dis (hoboken) 17(1):23\u201328. https:\/\/doi.org\/10.1002\/cld.1045","journal-title":"Clin Liver Dis (hoboken)"},{"key":"3752_CR3","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1146\/annurev-pathol-020117-043617","volume":"13","author":"JP Arab","year":"2018","unstructured":"Arab JP, Arrese M, Trauner M (2018) Recent insights into the pathogenesis of nonalcoholic fatty liver disease (in Eng). Annu Rev Pathol 13:321\u2013350. https:\/\/doi.org\/10.1146\/annurev-pathol-020117-043617","journal-title":"Annu Rev Pathol"},{"key":"3752_CR4","doi-asserted-by":"publisher","first-page":"186","DOI":"10.3389\/fendo.2018.00186","volume":"9","author":"E Belegri","year":"2018","unstructured":"Belegri E, Eggels L, La Fleur SE, Boelen A (2018) One-week exposure to a free-choice high-fat high-sugar diet does not interfere with the lipopolysaccharide-induced acute phase response in the hypothalamus of male rats (in Eng). Front Endocrinol (lausanne) 9:186. https:\/\/doi.org\/10.3389\/fendo.2018.00186","journal-title":"Front Endocrinol (lausanne)"},{"issue":"16","key":"3752_CR5","doi-asserted-by":"publisher","first-page":"715","DOI":"10.4254\/wjh.v9.i16.715","volume":"9","author":"M Benedict","year":"2017","unstructured":"Benedict M, Zhang X (2017) Non-alcoholic fatty liver disease: an expanded review (in Eng). World J Hepatol 9(16):715\u2013732. https:\/\/doi.org\/10.4254\/wjh.v9.i16.715","journal-title":"World J Hepatol"},{"issue":"3","key":"3752_CR6","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0151063","volume":"11","author":"AE Bigorgne","year":"2016","unstructured":"Bigorgne AE, John B, Ebrahimkhani MR, Shimizu-Albergine M, Campbell JS, Crispe IN (2016) TLR4-dependent secretion by hepatic stellate cells of the neutrophil-chemoattractant CXCL1 mediates liver response to gut microbiota (in Eng). PLoS ONE 11(3):e0151063. https:\/\/doi.org\/10.1371\/journal.pone.0151063","journal-title":"PLoS ONE"},{"issue":"1","key":"3752_CR7","doi-asserted-by":"publisher","first-page":"7842","DOI":"10.1038\/s41598-022-12004-y","volume":"12","author":"MM Bikbov","year":"2022","unstructured":"Bikbov MM et al (2022) Prevalence of non-alcoholic fatty liver disease in the Russian Ural Eye and Medical Study and the Ural Very Old Study (in Eng). Sci Rep 12(1):7842. https:\/\/doi.org\/10.1038\/s41598-022-12004-y","journal-title":"Sci Rep"},{"issue":"3","key":"3752_CR8","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1002\/hep.28356","volume":"63","author":"J Boursier","year":"2016","unstructured":"Boursier J et al (2016) The severity of nonalcoholic fatty liver disease is associated with gut dysbiosis and shift in the metabolic function of the gut microbiota (in Eng). Hepatology 63(3):764\u2013775. https:\/\/doi.org\/10.1002\/hep.28356","journal-title":"Hepatology"},{"issue":"5","key":"3752_CR9","doi-asserted-by":"publisher","first-page":"G413","DOI":"10.1152\/ajpgi.00361.2016","volume":"312","author":"K Brandl","year":"2017","unstructured":"Brandl K, Kumar V, Eckmann L (2017) Gut-liver axis at the frontier of host-microbial interactions (in Eng). Am J Physiol Gastrointest Liver Physiol 312(5):G413\u2013G419. https:\/\/doi.org\/10.1152\/ajpgi.00361.2016","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"3752_CR10","doi-asserted-by":"publisher","first-page":"725390","DOI":"10.3389\/fmed.2021.725390","volume":"8","author":"A Bruneau","year":"2021","unstructured":"Bruneau A, Hundertmark J, Guillot A, Tacke F (2021) Molecular and cellular mediators of the gut-liver axis in the progression of liver diseases (in Eng). Front Med (lausanne) 8:725390. https:\/\/doi.org\/10.3389\/fmed.2021.725390","journal-title":"Front Med (lausanne)"},{"issue":"8","key":"3752_CR11","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1016\/j.metabol.2015.12.012","volume":"65","author":"E Buzzetti","year":"2016","unstructured":"Buzzetti E, Pinzani M, Tsochatzis EA (2016) The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD) (in Eng). Metabolism 65(8):1038\u20131048. https:\/\/doi.org\/10.1016\/j.metabol.2015.12.012","journal-title":"Metabolism"},{"issue":"2","key":"3752_CR12","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1002\/hep.31056","volume":"72","author":"G Carpino","year":"2020","unstructured":"Carpino G et al (2020) Increased liver localization of lipopolysaccharides in human and experimental NAFLD (in Eng). Hepatology 72(2):470\u2013485. https:\/\/doi.org\/10.1002\/hep.31056","journal-title":"Hepatology"},{"issue":"1","key":"3752_CR13","doi-asserted-by":"publisher","first-page":"1406","DOI":"10.1038\/s41467-019-09455-9","volume":"10","author":"C Caussy","year":"2019","unstructured":"Caussy C et al (2019) A gut microbiome signature for cirrhosis due to nonalcoholic fatty liver disease (in Eng). Nat Commun 10(1):1406. https:\/\/doi.org\/10.1038\/s41467-019-09455-9","journal-title":"Nat Commun"},{"issue":"6","key":"3752_CR14","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1016\/j.jceh.2019.06.004","volume":"9","author":"NS Choudhary","year":"2019","unstructured":"Choudhary NS, Kumar N, Duseja A (2019) Peroxisome proliferator-activated receptors and their agonists in nonalcoholic fatty liver disease (in Eng). J Clin Exp Hepatol 9(6):731\u2013739. https:\/\/doi.org\/10.1016\/j.jceh.2019.06.004","journal-title":"J Clin Exp Hepatol"},{"key":"3752_CR15","doi-asserted-by":"publisher","first-page":"154338","DOI":"10.1016\/j.metabol.2020.154338","volume":"114","author":"A Christofides","year":"2021","unstructured":"Christofides A, Konstantinidou E, Jani C, Boussiotis VA (2021) The role of peroxisome proliferator-activated receptors (PPAR) in immune responses. Metabolism 114:154338. https:\/\/doi.org\/10.1016\/j.metabol.2020.154338","journal-title":"Metabolism"},{"issue":"4","key":"3752_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinre.2021.101710","volume":"45","author":"Y Colak","year":"2021","unstructured":"Colak Y et al (2021) Pathogenetic mechanisms of nonalcoholic fatty liver disease and inhibition of the inflammasome as a new therapeutic target (in Eng). Clin Res Hepatol Gastroenterol 45(4):101710. https:\/\/doi.org\/10.1016\/j.clinre.2021.101710","journal-title":"Clin Res Hepatol Gastroenterol"},{"issue":"11","key":"3752_CR17","doi-asserted-by":"publisher","first-page":"1812","DOI":"10.1136\/gutjnl-2015-309957","volume":"65","author":"F De Filippis","year":"2016","unstructured":"De Filippis F et al (2016) High-level adherence to a Mediterranean diet beneficially impacts the gut microbiota and associated metabolome (in Eng). Gut 65(11):1812\u20131821. https:\/\/doi.org\/10.1136\/gutjnl-2015-309957","journal-title":"Gut"},{"issue":"5","key":"3752_CR18","doi-asserted-by":"publisher","first-page":"1738","DOI":"10.1002\/hep.26695","volume":"59","author":"S De Minicis","year":"2014","unstructured":"De Minicis S et al (2014) Dysbiosis contributes to fibrogenesis in the course of chronic liver injury in mice (in Eng). Hepatology 59(5):1738\u20131749. https:\/\/doi.org\/10.1002\/hep.26695","journal-title":"Hepatology"},{"key":"3752_CR19","doi-asserted-by":"publisher","first-page":"730","DOI":"10.3389\/fphar.2020.00730","volume":"11","author":"J Decara","year":"2020","unstructured":"Decara J et al (2020) Peroxisome proliferator-activated receptors: experimental targeting for the treatment of inflammatory bowel diseases (in Eng). Front Pharmacol 11:730. https:\/\/doi.org\/10.3389\/fphar.2020.00730","journal-title":"Front Pharmacol"},{"issue":"1","key":"3752_CR20","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1084\/jem.20180448","volume":"216","author":"J Durack","year":"2019","unstructured":"Durack J, Lynch SV (2019) The gut microbiome: relationships with disease and opportunities for therapy (in Eng). J Exp Med 216(1):20\u201340. https:\/\/doi.org\/10.1084\/jem.20180448","journal-title":"J Exp Med"},{"issue":"4","key":"3752_CR21","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1007\/s10096-019-03746-1","volume":"39","author":"H Ebrahimzadeh Leylabadlo","year":"2020","unstructured":"Ebrahimzadeh Leylabadlo H et al (2020) Non-alcoholic fatty liver diseases: from role of gut microbiota to microbial-based therapies (in Eng). Eur J Clin Microbiol Infect Dis 39(4):613\u2013627. https:\/\/doi.org\/10.1007\/s10096-019-03746-1","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"5","key":"3752_CR22","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1016\/j.jcmgh.2016.04.007","volume":"2","author":"L Etienne-Mesmin","year":"2016","unstructured":"Etienne-Mesmin L, Vijay-Kumar M, Gewirtz AT, Chassaing B (2016) Hepatocyte toll-like receptor 5 promotes bacterial clearance and protects mice against high-fat diet-induced liver disease (in Eng). Cell Mol Gastroenterol Hepatol 2(5):584\u2013604. https:\/\/doi.org\/10.1016\/j.jcmgh.2016.04.007","journal-title":"Cell Mol Gastroenterol Hepatol"},{"key":"3752_CR23","doi-asserted-by":"publisher","first-page":"205873922110147","DOI":"10.1177\/20587392211014762","volume":"19","author":"Y Fang","year":"2021","unstructured":"Fang Y, Zhou L, Hu X, Guo J, Liao J, Zhang Z (2021) TLR4-MyD88-NF-\u03baB signaling pathway contributes to the progression of secondary hepatic injury and fibrosis in hepatolithiasis. Eur J Inflamm 19:20587392211014760. https:\/\/doi.org\/10.1177\/20587392211014762","journal-title":"Eur J Inflamm"},{"key":"3752_CR24","doi-asserted-by":"publisher","DOI":"10.1128\/mBio.03263-19","author":"N Fei","year":"2020","unstructured":"Fei N et al (2020) Endotoxin producers overgrowing in human gut microbiota as the causative agents for nonalcoholic fatty liver disease (in Eng). Mbio. https:\/\/doi.org\/10.1128\/mBio.03263-19","journal-title":"Mbio"},{"key":"3752_CR25","doi-asserted-by":"publisher","DOI":"10.3390\/cells9071638","author":"A Fougerat","year":"2020","unstructured":"Fougerat A, Montagner A, Loiseau N, Guillou H, Wahli W (2020) Peroxisome proliferator-activated receptors and their novel ligands as candidates for the treatment of non-alcoholic fatty liver disease (in Eng). Cells. https:\/\/doi.org\/10.3390\/cells9071638","journal-title":"Cells"},{"issue":"1","key":"3752_CR26","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1038\/s41575-020-00366-5","volume":"18","author":"S Francque","year":"2021","unstructured":"Francque S et al (2021) Nonalcoholic steatohepatitis: the role of peroxisome proliferator-activated receptors (in Eng). Nat Rev Gastroenterol Hepatol 18(1):24\u201339. https:\/\/doi.org\/10.1038\/s41575-020-00366-5","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"3752_CR27","doi-asserted-by":"publisher","DOI":"10.22541\/au.169667643.30628951\/v1","author":"SK Gruzdev","year":"2023","unstructured":"Gruzdev SK, Podoprigora IV, Gizinger OA (2023) Immunological interactions between the gut microbiome and the liver in non-alcoholic fatty liver disease: mechanisms and potential therapeutic targets. Authorea.  https:\/\/doi.org\/10.22541\/au.169667643.30628951\/v1","journal-title":"Authorea"},{"key":"3752_CR28","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines10030550","author":"H Gupta","year":"2022","unstructured":"Gupta H et al (2022) Gut microbiome in non-alcoholic fatty liver disease: from mechanisms to therapeutic role (in Eng). Biomedicines. https:\/\/doi.org\/10.3390\/biomedicines10030550","journal-title":"Biomedicines"},{"issue":"12","key":"3752_CR29","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1080\/10408398.2021.1966738","volume":"63","author":"H Han","year":"2023","unstructured":"Han H et al (2023) Intestinal dysbiosis in nonalcoholic fatty liver disease (NAFLD): focusing on the gut-liver axis (in Eng). Crit Rev Food Sci Nutr 63(12):1689\u20131706. https:\/\/doi.org\/10.1080\/10408398.2021.1966738","journal-title":"Crit Rev Food Sci Nutr"},{"key":"3752_CR30","doi-asserted-by":"publisher","DOI":"10.3390\/microorganisms9050957","author":"T Hrncir","year":"2021","unstructured":"Hrncir T et al (2021) Gut microbiota and NAFLD: pathogenetic mechanisms, microbiota signatures, and therapeutic interventions (in Eng). Microorganisms. https:\/\/doi.org\/10.3390\/microorganisms9050957","journal-title":"Microorganisms"},{"issue":"7","key":"3752_CR31","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1038\/s41577-021-00639-3","volume":"22","author":"T Huby","year":"2022","unstructured":"Huby T, Gautier EL (2022) Immune cell-mediated features of non-alcoholic steatohepatitis. Nat Rev Immunol 22(7):429\u2013443. https:\/\/doi.org\/10.1038\/s41577-021-00639-3","journal-title":"Nat Rev Immunol"},{"key":"3752_CR32","doi-asserted-by":"publisher","DOI":"10.3390\/nu10020203","author":"H Hug","year":"2018","unstructured":"Hug H, Mohajeri MH, La Fata G (2018) Toll-like receptors: regulators of the immune response in the human gut (in Eng). Nutrients. https:\/\/doi.org\/10.3390\/nu10020203","journal-title":"Nutrients"},{"key":"3752_CR33","doi-asserted-by":"publisher","first-page":"592157","DOI":"10.3389\/fendo.2020.592157","volume":"11","author":"K Jadhav","year":"2020","unstructured":"Jadhav K, Cohen TS (2020) Can you trust your gut? Implicating a disrupted intestinal microbiome in the progression of NAFLD\/NASH (in Eng). Front Endocrinol (lausanne) 11:592157. https:\/\/doi.org\/10.3389\/fendo.2020.592157","journal-title":"Front Endocrinol (lausanne)"},{"issue":"29","key":"3752_CR34","doi-asserted-by":"publisher","first-page":"8787","DOI":"10.3748\/wjg.v21.i29.8787","volume":"21","author":"SM Jandhyala","year":"2015","unstructured":"Jandhyala SM, Talukdar R, Subramanyam C, Vuyyuru H, Sasikala M, Nageshwar Reddy D (2015) Role of the normal gut microbiota (in Eng). World J Gastroenterol 21(29):8787\u20138803. https:\/\/doi.org\/10.3748\/wjg.v21.i29.8787","journal-title":"World J Gastroenterol"},{"key":"3752_CR35","doi-asserted-by":"publisher","DOI":"10.3390\/nu11081712","author":"Y Ji","year":"2019","unstructured":"Ji Y, Yin Y, Li Z, Zhang W (2019) Gut microbiota-derived components and metabolites in the progression of non-alcoholic fatty liver disease (NAFLD) (in Eng). Nutrients. https:\/\/doi.org\/10.3390\/nu11081712","journal-title":"Nutrients"},{"key":"3752_CR36","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21093066","author":"Y Ji","year":"2020","unstructured":"Ji Y, Yin Y, Sun L, Zhang W (2020) The molecular and mechanistic insights based on gut-liver axis: nutritional target for non-alcoholic fatty liver disease (NAFLD) improvement (in Eng). Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms21093066","journal-title":"Int J Mol Sci"},{"key":"3752_CR37","doi-asserted-by":"publisher","first-page":"8096","DOI":"10.1038\/srep08096","volume":"5","author":"W Jiang","year":"2015","unstructured":"Jiang W et al (2015) Dysbiosis gut microbiota associated with inflammation and impaired mucosal immune function in intestine of humans with non-alcoholic fatty liver disease (in Eng). Sci Rep 5:8096. https:\/\/doi.org\/10.1038\/srep08096","journal-title":"Sci Rep"},{"key":"3752_CR38","doi-asserted-by":"publisher","DOI":"10.1016\/j.etap.2022.103819","volume":"90","author":"M Jin","year":"2022","unstructured":"Jin M et al (2022) Enterobacter cloacae aggravates metabolic disease by inducing inflammation and lipid accumulation (in Eng). Environ Toxicol Pharmacol 90:103819. https:\/\/doi.org\/10.1016\/j.etap.2022.103819","journal-title":"Environ Toxicol Pharmacol"},{"issue":"17","key":"3752_CR39","doi-asserted-by":"publisher","first-page":"1993","DOI":"10.3748\/wjg.v26.i17.1993","volume":"26","author":"A Katsarou","year":"2020","unstructured":"Katsarou A, Moustakas II, Pyrina I, Lembessis P, Koutsilieris M, Chatzigeorgiou A (2020) Metabolic inflammation as an instigator of fibrosis during non-alcoholic fatty liver disease (in Eng). World J Gastroenterol 26(17):1993\u20132011. https:\/\/doi.org\/10.3748\/wjg.v26.i17.1993","journal-title":"World J Gastroenterol"},{"issue":"5","key":"3752_CR40","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0198262","volume":"13","author":"A Keskitalo","year":"2018","unstructured":"Keskitalo A et al (2018) Enterobacter cloacae administration induces hepatic damage and subcutaneous fat accumulation in high-fat diet fed mice (in Eng). PLoS ONE 13(5):e0198262. https:\/\/doi.org\/10.1371\/journal.pone.0198262","journal-title":"PLoS ONE"},{"key":"3752_CR41","doi-asserted-by":"publisher","first-page":"770986","DOI":"10.3389\/fendo.2021.770986","volume":"12","author":"T Kessoku","year":"2021","unstructured":"Kessoku T et al (2021) Endotoxins and non-alcoholic fatty liver disease (in Eng). Front Endocrinol (lausanne) 12:770986. https:\/\/doi.org\/10.3389\/fendo.2021.770986","journal-title":"Front Endocrinol (lausanne)"},{"key":"3752_CR42","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2022.106507","volume":"185","author":"S Khanmohammadi","year":"2022","unstructured":"Khanmohammadi S, Kuchay MS (2022) Toll-like receptors and metabolic (dysfunction)-associated fatty liver disease (in Eng). Pharmacol Res 185:106507. https:\/\/doi.org\/10.1016\/j.phrs.2022.106507","journal-title":"Pharmacol Res"},{"key":"3752_CR43","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.673708","volume":"12","author":"Y Kinashi","year":"2021","unstructured":"Kinashi Y, Hase K (2021) Partners in leaky gut syndrome: intestinal dysbiosis and autoimmunity (in Eng). Front Immunol 12:673708. https:\/\/doi.org\/10.3389\/fimmu.2021.673708","journal-title":"Front Immunol"},{"key":"3752_CR44","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.201809302","author":"AA Kolodziejczyk","year":"2019","unstructured":"Kolodziejczyk AA, Zheng D, Shibolet O, Elinav E (2019) The role of the microbiome in NAFLD and NASH (in Eng). EMBO Mol Med. https:\/\/doi.org\/10.15252\/emmm.201809302","journal-title":"EMBO Mol Med"},{"issue":"1","key":"3752_CR45","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1038\/s41575-021-00523-4","volume":"19","author":"JV Lazarus","year":"2022","unstructured":"Lazarus JV et al (2022) Advancing the global public health agenda for NAFLD: a consensus statement (in Eng). Nat Rev Gastroenterol Hepatol 19(1):60\u201378. https:\/\/doi.org\/10.1038\/s41575-021-00523-4","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"3752_CR46","doi-asserted-by":"publisher","first-page":"13839","DOI":"10.1038\/ncomms13839","volume":"7","author":"F Li","year":"2017","unstructured":"Li F et al (2017) The microbiota maintain homeostasis of liver-resident \u03b3\u03b4T-17 cells in a lipid antigen\/CD1d-dependent manner (in Eng). Nat Commun 7:13839. https:\/\/doi.org\/10.1038\/ncomms13839","journal-title":"Nat Commun"},{"issue":"3","key":"3752_CR47","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1016\/j.jceh.2021.11.011","volume":"12","author":"Q Li","year":"2022","unstructured":"Li Q, Rempel JD, Yang J, Minuk GY (2022) The effects of pathogen-associated molecular patterns on peripheral blood monocytes in patients with non-alcoholic fatty liver disease (in Eng). J Clin Exp Hepatol 12(3):808\u2013817. https:\/\/doi.org\/10.1016\/j.jceh.2021.11.011","journal-title":"J Clin Exp Hepatol"},{"issue":"Suppl 2","key":"3752_CR48","doi-asserted-by":"publisher","first-page":"S133","DOI":"10.1093\/clinids\/12.supplement_2.s133","volume":"12","author":"AA Lindberg","year":"1990","unstructured":"Lindberg AA, Weintraub A, Z\u00e4hringer U, Rietschel ET (1990) Structure-activity relationships in lipopolysaccharides of Bacteroides fragilis (in Eng). Rev Infect Dis 12(Suppl 2):S133\u2013S141. https:\/\/doi.org\/10.1093\/clinids\/12.supplement_2.s133","journal-title":"Rev Infect Dis"},{"key":"3752_CR49","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.968799","volume":"13","author":"J Liu","year":"2022","unstructured":"Liu J, Wu A, Cai J, She ZG, Li H (2022) The contribution of the gut-liver axis to the immune signaling pathway of NAFLD (in Eng). Front Immunol 13:968799. https:\/\/doi.org\/10.3389\/fimmu.2022.968799","journal-title":"Front Immunol"},{"issue":"5","key":"3752_CR50","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1016\/j.cmet.2017.04.001","volume":"25","author":"R Loomba","year":"2017","unstructured":"Loomba R et al (2017) Gut microbiome-based metagenomic signature for non-invasive detection of advanced fibrosis in human nonalcoholic fatty liver disease (in Eng). Cell Metab 25(5):1054-1062.e5. https:\/\/doi.org\/10.1016\/j.cmet.2017.04.001","journal-title":"Cell Metab"},{"key":"3752_CR51","doi-asserted-by":"publisher","first-page":"121614","DOI":"10.1016\/j.lfs.2023.121614","volume":"321","author":"L Luo","year":"2023","unstructured":"Luo L, Chang Y, Sheng L (2023) Gut-liver axis in the progression of nonalcoholic fatty liver disease: from the microbial derivatives-centered perspective (in Eng). Life Sci 321:121614. https:\/\/doi.org\/10.1016\/j.lfs.2023.121614","journal-title":"Life Sci"},{"issue":"6","key":"3752_CR52","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1016\/j.jhep.2019.08.005","volume":"71","author":"J Mouries","year":"2019","unstructured":"Mouries J et al (2019) Microbiota-driven gut vascular barrier disruption is a prerequisite for non-alcoholic steatohepatitis development (in Eng). J Hepatol 71(6):1216\u20131228. https:\/\/doi.org\/10.1016\/j.jhep.2019.08.005","journal-title":"J Hepatol"},{"issue":"5","key":"3752_CR53","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1016\/j.jhep.2017.01.022","volume":"66","author":"AR Mridha","year":"2017","unstructured":"Mridha AR et al (2017) NLRP3 inflammasome blockade reduces liver inflammation and fibrosis in experimental NASH in mice (in Eng). J Hepatol 66(5):1037\u20131046. https:\/\/doi.org\/10.1016\/j.jhep.2017.01.022","journal-title":"J Hepatol"},{"issue":"2","key":"3752_CR54","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1002\/hep4.1134","volume":"2","author":"P Nasr","year":"2018","unstructured":"Nasr P, Ignatova S, Kechagias S, Ekstedt M (2018) Natural history of nonalcoholic fatty liver disease: a prospective follow-up study with serial biopsies (in Eng). Hepatol Commun 2(2):199\u2013210. https:\/\/doi.org\/10.1002\/hep4.1134","journal-title":"Hepatol Commun"},{"issue":"1","key":"3752_CR55","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1159\/000518407","volume":"14","author":"M Nati","year":"2022","unstructured":"Nati M, Chung KJ, Chavakis T (2022) The role of innate immune cells in nonalcoholic fatty liver disease (in Eng). J Innate Immun 14(1):31\u201341. https:\/\/doi.org\/10.1159\/000518407","journal-title":"J Innate Immun"},{"issue":"12","key":"3752_CR56","doi-asserted-by":"publisher","first-page":"2698","DOI":"10.1016\/j.ajpath.2017.08.005","volume":"187","author":"M Nighot","year":"2017","unstructured":"Nighot M et al (2017) Lipopolysaccharide-induced increase in intestinal epithelial tight permeability is mediated by toll-like receptor 4\/myeloid differentiation primary response 88 (MyD88) activation of myosin light chain kinase expression (in Eng). Am J Pathol 187(12):2698\u20132710. https:\/\/doi.org\/10.1016\/j.ajpath.2017.08.005","journal-title":"Am J Pathol"},{"key":"3752_CR57","doi-asserted-by":"publisher","first-page":"2624941","DOI":"10.1155\/2019\/2624941","volume":"2019","author":"L Ning","year":"2019","unstructured":"Ning L, Lou X, Zhang F, Xu G (2019) Nuclear receptors in the pathogenesis and management of inflammatory bowel disease (in Eng). Mediat Inflamm 2019:2624941. https:\/\/doi.org\/10.1155\/2019\/2624941","journal-title":"Mediat Inflamm"},{"issue":"1","key":"3752_CR58","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1038\/s41598-023-27885-w","volume":"13","author":"KK Oh","year":"2023","unstructured":"Oh KK et al (2023) The identification of metabolites from gut microbiota in NAFLD via network pharmacology (in Eng). Sci Rep 13(1):724. https:\/\/doi.org\/10.1038\/s41598-023-27885-w","journal-title":"Sci Rep"},{"issue":"4","key":"3752_CR59","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1002\/hep4.1479","volume":"4","author":"G Parthasarathy","year":"2020","unstructured":"Parthasarathy G, Revelo X, Malhi H (2020) Pathogenesis of nonalcoholic steatohepatitis: an overview (in Eng). Hepatol Commun 4(4):478\u2013492. https:\/\/doi.org\/10.1002\/hep4.1479","journal-title":"Hepatol Commun"},{"issue":"1","key":"3752_CR60","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1186\/s12902-022-00980-1","volume":"22","author":"S Pouwels","year":"2022","unstructured":"Pouwels S et al (2022) Non-alcoholic fatty liver disease (NAFLD): a review of pathophysiology, clinical management and effects of weight loss (in Eng). BMC Endocr Disord 22(1):63. https:\/\/doi.org\/10.1186\/s12902-022-00980-1","journal-title":"BMC Endocr Disord"},{"issue":"48","key":"3752_CR61","doi-asserted-by":"publisher","first-page":"7603","DOI":"10.3748\/wjg.v26.i48.7603","volume":"26","author":"X Qi","year":"2020","unstructured":"Qi X et al (2020) Gut microbiota mediated molecular events and therapy in liver diseases (in Eng). World J Gastroenterol 26(48):7603\u20137618. https:\/\/doi.org\/10.3748\/wjg.v26.i48.7603","journal-title":"World J Gastroenterol"},{"issue":"9","key":"3752_CR62","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1016\/S2468-1253(22)00165-0","volume":"7","author":"K Riazi","year":"2022","unstructured":"Riazi K et al (2022) The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis (in Eng). Lancet Gastroenterol Hepatol 7(9):851\u2013861. https:\/\/doi.org\/10.1016\/S2468-1253(22)00165-0","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"3752_CR63","doi-asserted-by":"publisher","DOI":"10.1097\/HEP.0000000000000323","author":"ME Rinella","year":"2023","unstructured":"Rinella ME et al (2023) AASLD practice guidance on the clinical assessment and management of nonalcoholic fatty liver disease (in Eng). Hepatology. https:\/\/doi.org\/10.1097\/HEP.0000000000000323","journal-title":"Hepatology"},{"issue":"3","key":"3752_CR64","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1089\/ars.2017.7418","volume":"30","author":"M Salmi","year":"2019","unstructured":"Salmi M, Jalkanen S (2019) Vascular adhesion protein-1: a cell surface amine oxidase in translation (in Eng). Antioxid Redox Signal 30(3):314\u2013332. https:\/\/doi.org\/10.1089\/ars.2017.7418","journal-title":"Antioxid Redox Signal"},{"key":"3752_CR65","doi-asserted-by":"publisher","first-page":"1157023","DOI":"10.1155\/2021\/1157023","volume":"2021","author":"AS Sameer","year":"2021","unstructured":"Sameer AS, Nissar S (2021) Toll-like receptors (tlrs): structure, functions, signaling, and role of their polymorphisms in colorectal cancer susceptibility (in Eng). Biomed Res Int 2021:1157023. https:\/\/doi.org\/10.1155\/2021\/1157023","journal-title":"Biomed Res Int"},{"issue":"4","key":"3752_CR66","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1053\/j.gastro.2019.06.028","volume":"157","author":"JB Schwimmer","year":"2019","unstructured":"Schwimmer JB et al (2019) Microbiome Signatures associated with steatohepatitis and moderate to severe fibrosis in children with nonalcoholic fatty liver disease (in Eng). Gastroenterology 157(4):1109\u20131122. https:\/\/doi.org\/10.1053\/j.gastro.2019.06.028","journal-title":"Gastroenterology"},{"issue":"4","key":"3752_CR67","doi-asserted-by":"publisher","first-page":"G270","DOI":"10.1152\/ajpgi.00304.2014","volume":"309","author":"T Sharifnia","year":"2015","unstructured":"Sharifnia T et al (2015) Hepatic TLR4 signaling in obese NAFLD (in Eng). Am J Physiol Gastrointest Liv Physiol 309(4):G270\u2013G278. https:\/\/doi.org\/10.1152\/ajpgi.00304.2014","journal-title":"Am J Physiol Gastrointest Liv Physiol"},{"issue":"1","key":"3752_CR68","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1093\/ajcn\/nqz042","volume":"110","author":"SR Sharpton","year":"2019","unstructured":"Sharpton SR, Maraj B, Harding-Theobald E, Vittinghoff E, Terrault NA (2019) Gut microbiome-targeted therapies in nonalcoholic fatty liver disease: a systematic review, meta-analysis, and meta-regression (in Eng). Am J Clin Nutr 110(1):139\u2013149. https:\/\/doi.org\/10.1093\/ajcn\/nqz042","journal-title":"Am J Clin Nutr"},{"issue":"1","key":"3752_CR69","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.cmet.2020.11.010","volume":"33","author":"SR Sharpton","year":"2021","unstructured":"Sharpton SR, Schnabl B, Knight R, Loomba R (2021) Current concepts, opportunities, and challenges of gut microbiome-based personalized medicine in nonalcoholic fatty liver disease (in Eng). Cell Metab 33(1):21\u201332. https:\/\/doi.org\/10.1016\/j.cmet.2020.11.010","journal-title":"Cell Metab"},{"issue":"22","key":"3752_CR70","doi-asserted-by":"publisher","first-page":"3042","DOI":"10.1080\/15384101.2020.1829800","volume":"19","author":"S Shen","year":"2020","unstructured":"Shen S, Wang K, Zhi Y, Shen W, Huang L (2020) Gypenosides improves nonalcoholic fatty liver disease induced by high-fat diet induced through regulating LPS\/TLR4 signaling pathway (in Eng). Cell Cycle 19(22):3042\u20133053. https:\/\/doi.org\/10.1080\/15384101.2020.1829800","journal-title":"Cell Cycle"},{"issue":"11","key":"3752_CR71","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1042\/BCJ20160510","volume":"474","author":"E Thursby","year":"2017","unstructured":"Thursby E, Juge N (2017) Introduction to the human gut microbiota (in Eng). Biochem J 474(11):1823\u20131836. https:\/\/doi.org\/10.1042\/BCJ20160510","journal-title":"Biochem J"},{"issue":"1","key":"3752_CR72","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinre.2022.102068","volume":"47","author":"H Tian","year":"2023","unstructured":"Tian H et al (2023) Global burden of non-alcoholic fatty liver disease in 204 countries and territories from 1990 to 2019 (in Eng). Clin Res Hepatol Gastroenterol 47(1):102068. https:\/\/doi.org\/10.1016\/j.clinre.2022.102068","journal-title":"Clin Res Hepatol Gastroenterol"},{"issue":"1","key":"3752_CR73","doi-asserted-by":"publisher","first-page":"13","DOI":"10.3390\/sci3010013","volume":"3","author":"R Toivonen","year":"2021","unstructured":"Toivonen R et al (2021) Vascular adhesion protein 1 mediates gut microbial flagellin-induced inflammation, leukocyte infiltration, and hepatic steatosis. Sci 3(1):13","journal-title":"Sci"},{"issue":"12","key":"3752_CR74","doi-asserted-by":"publisher","first-page":"1588","DOI":"10.1038\/s41564-020-00801-y","volume":"5","author":"P Tourlomousis","year":"2020","unstructured":"Tourlomousis P et al (2020) Modifying bacterial flagellin to evade Nod-like Receptor CARD 4 recognition enhances protective immunity against Salmonella (in Eng). Nat Microbiol 5(12):1588\u20131597. https:\/\/doi.org\/10.1038\/s41564-020-00801-y","journal-title":"Nat Microbiol"},{"issue":"1","key":"3752_CR75","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1136\/gutjnl-2021-324305","volume":"71","author":"M Trauner","year":"2022","unstructured":"Trauner M, Fuchs CD (2022) Novel therapeutic targets for cholestatic and fatty liver disease (in Eng). Gut 71(1):194\u2013209. https:\/\/doi.org\/10.1136\/gutjnl-2021-324305","journal-title":"Gut"},{"issue":"5975","key":"3752_CR76","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1126\/science.1179721","volume":"328","author":"M Vijay-Kumar","year":"2010","unstructured":"Vijay-Kumar M et al (2010) Metabolic syndrome and altered gut microbiota in mice lacking Toll-like receptor 5 (in Eng). Science 328(5975):228\u2013231. https:\/\/doi.org\/10.1126\/science.1179721","journal-title":"Science"},{"key":"3752_CR77","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21062061","author":"Y Wang","year":"2020","unstructured":"Wang Y, Nakajima T, Gonzalez FJ, Tanaka N (2020) PPARs as metabolic regulators in the liver: lessons from liver-specific PPAR-null mice (in Eng). Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms21062061","journal-title":"Int J Mol Sci"},{"issue":"1","key":"3752_CR78","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1038\/s41423-020-00592-6","volume":"18","author":"R Wang","year":"2021","unstructured":"Wang R, Tang R, Li B, Ma X, Schnabl B, Tilg H (2021a) Gut microbiome, liver immunology, and liver diseases (in eng). Cell Mol Immunol 18(1):4\u201317. https:\/\/doi.org\/10.1038\/s41423-020-00592-6","journal-title":"Cell Mol Immunol"},{"issue":"1","key":"3752_CR79","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1038\/s41423-020-00579-3","volume":"18","author":"H Wang","year":"2021","unstructured":"Wang H, Mehal W, Nagy LE, Rotman Y (2021b) Immunological mechanisms and therapeutic targets of fatty liver diseases (in Eng). Cell Mol Immunol 18(1):73\u201391. https:\/\/doi.org\/10.1038\/s41423-020-00579-3","journal-title":"Cell Mol Immunol"},{"key":"3752_CR80","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2022.759306","volume":"12","author":"L Xue","year":"2022","unstructured":"Xue L, Deng Z, Luo W, He X, Chen Y (2022) Effect of fecal microbiota transplantation on non-alcoholic fatty liver disease: a randomized clinical trial (in Eng). Front Cell Infect Microbiol 12:759306. https:\/\/doi.org\/10.3389\/fcimb.2022.759306","journal-title":"Front Cell Infect Microbiol"},{"key":"3752_CR81","doi-asserted-by":"publisher","first-page":"1786","DOI":"10.3389\/fmicb.2016.01786","volume":"7","author":"H Yan","year":"2016","unstructured":"Yan H, Fei N, Wu G, Zhang C, Zhao L, Zhang M (2016) Regulated inflammation and lipid metabolism in colon mRNA expressions of obese germfree mice responding to (in Eng). Front Microbiol 7:1786. https:\/\/doi.org\/10.3389\/fmicb.2016.01786","journal-title":"Front Microbiol"},{"issue":"3","key":"3752_CR82","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1016\/j.jcmgh.2016.12.004","volume":"3","author":"L Yang","year":"2017","unstructured":"Yang L et al (2017) TRIF differentially regulates hepatic steatosis and inflammation\/fibrosis in mice (in Eng). Cell Mol Gastroenterol Hepatol 3(3):469\u2013483. https:\/\/doi.org\/10.1016\/j.jcmgh.2016.12.004","journal-title":"Cell Mol Gastroenterol Hepatol"},{"issue":"1","key":"3752_CR83","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1002\/hep.28431","volume":"64","author":"ZM Younossi","year":"2016","unstructured":"Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M (2016) Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes (in Eng). Hepatology 64(1):73\u201384. https:\/\/doi.org\/10.1002\/hep.28431","journal-title":"Hepatology"},{"key":"3752_CR84","doi-asserted-by":"publisher","DOI":"10.1097\/HEP.0000000000000004","author":"ZM Younossi","year":"2023","unstructured":"Younossi ZM, Golabi P, Paik JM, Henry A, Van Dongen C, Henry L (2023) The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review (in Eng). Hepatology. https:\/\/doi.org\/10.1097\/HEP.0000000000000004","journal-title":"Hepatology"},{"key":"3752_CR85","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.783393","volume":"12","author":"S Yu","year":"2021","unstructured":"Yu S, Li C, Ji G, Zhang L (2021) The contribution of dietary fructose to non-alcoholic fatty liver disease (in Eng). Front Pharmacol 12:783393. https:\/\/doi.org\/10.3389\/fphar.2021.783393","journal-title":"Front Pharmacol"},{"issue":"6","key":"3752_CR86","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1016\/j.cmet.2019.11.006","volume":"30","author":"J Yuan","year":"2019","unstructured":"Yuan J et al (2019) Fatty liver disease caused by high-alcohol-producing klebsiella pneumoniae (in Eng). Cell Metab 30(6):1172. https:\/\/doi.org\/10.1016\/j.cmet.2019.11.006","journal-title":"Cell Metab"},{"key":"3752_CR87","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2020.535940","volume":"10","author":"Y Zhang","year":"2020","unstructured":"Zhang Y et al (2020) NF73-1 isolated from NASH patients aggravates NAFLD in mice by translocating into the liver and stimulating M1 polarization (in Eng). Front Cell Infect Microbiol 10:535940. https:\/\/doi.org\/10.3389\/fcimb.2020.535940","journal-title":"Front Cell Infect Microbiol"},{"issue":"3","key":"3752_CR88","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1016\/j.ajpath.2019.11.012","volume":"190","author":"Z Zhou","year":"2020","unstructured":"Zhou Z, Kim JW, Qi J, Eo SK, Lim CW, Kim B (2020) Toll-like receptor 5 signaling ameliorates liver fibrosis by inducing interferon \u03b2-modulated IL-1 receptor antagonist in mice (in Eng). Am J Pathol 190(3):614\u2013629. https:\/\/doi.org\/10.1016\/j.ajpath.2019.11.012","journal-title":"Am J Pathol"},{"key":"3752_CR89","doi-asserted-by":"publisher","first-page":"11","DOI":"10.20517\/2394-5079.2020.134","volume":"7","author":"J Zhou","year":"2021","unstructured":"Zhou J, Tripathi M, Sinha RA, Singh BK, Yen PM (2021) Gut microbiota and their metabolites in the progression of non-alcoholic fatty liver disease (in Eng). Hepatoma Res 7:11. https:\/\/doi.org\/10.20517\/2394-5079.2020.134","journal-title":"Hepatoma Res"},{"key":"3752_CR90","doi-asserted-by":"publisher","DOI":"10.3390\/ijms222011128","author":"S Ziolkowska","year":"2021","unstructured":"Ziolkowska S, Binienda A, Jab\u0142kowski M, Szemraj J, Czarny P (2021) The interplay between insulin resistance, inflammation, oxidative stress, base excision repair and metabolic syndrome in nonalcoholic fatty liver disease (in Eng). Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms222011128","journal-title":"Int J Mol Sci"}],"container-title":["Archives of Microbiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00203-023-03752-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00203-023-03752-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00203-023-03752-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,11]],"date-time":"2024-02-11T08:02:27Z","timestamp":1707638547000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00203-023-03752-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,13]]},"references-count":90,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["3752"],"URL":"https:\/\/doi.org\/10.1007\/s00203-023-03752-0","relation":{"has-preprint":[{"id-type":"doi","id":"10.22541\/au.169667643.30628951\/v1","asserted-by":"object"}]},"ISSN":["0302-8933","1432-072X"],"issn-type":[{"value":"0302-8933","type":"print"},{"value":"1432-072X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,13]]},"assertion":[{"value":"10 October 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 November 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 November 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 January 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"S. K. Gruzdev declares that he has no conflict of interest. I. V. Podoprigora, declares that she has no conflict of interest. O. A. Gizinger declares that she has no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This article does not contain any studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}],"article-number":"62"}}